64318-08-7

Usage

Uses

Used in Pharmaceutical Industry:
4-CHLORO-NAPHTHALENE-1-SULFONYL CHLORIDE is used as a precursor in the synthesis of pharmaceuticals for its reactivity and ability to form strong covalent bonds, making it a valuable building block in the development of various medicinal compounds.
Used in Dye Industry:
4-CHLORO-NAPHTHALENE-1-SULFONYL CHLORIDE is used as a precursor in the synthesis of dyes due to its reactivity and ability to form strong covalent bonds, contributing to the creation of a wide range of colorants for various applications.
Used in Organic Synthesis:
4-CHLORO-NAPHTHALENE-1-SULFONYL CHLORIDE is used as a reagent in organic synthesis for its reactivity and ability to form strong covalent bonds, making it a valuable building block in the creation of various organic compounds.
It is important to handle and use this chemical with caution, as it can be harmful if inhaled, swallowed, or in contact with skin.

InChI:InChI=1/C10H6Cl2O2S/c11-9-5-6-10(15(12,13)14)8-4-2-1-3-7(8)9/h1-6H

Upstream product

• 6328-72-9 4-chloro-1-naphthylsulphonic acid 
• 90-13-1 1-Chloronaphthalene 

Downstream Products

• 6334-37-8 1-chloro-4-iodo-naphthalene 
• 6328-72-9 4-chloro-1-naphthylsulphonic acid 
• 1089187-48-3 4-chloro-1-naphthalenesulfonyl-N-{2,3-dihydro-2,2-dimethyl-7-{2-[4-(2-methoxy-5-trifluoromethyl-phenyl)-piperazine]-ethoxy}-benzofuran-5-yl}-amide hydrochloride 
• 1825-31-6 1,4-dichloronaphthalene 

Relevant academic research and scientific papers

From hit to lead: Structure-based discovery of naphthalene-1-sulfonamide derivatives as potent and selective inhibitors of fatty acid binding protein 4

Fatty acid binding protein 4 (FABP4) plays a critical role in metabolism and inflammatory processes and therefore is a potential therapeutic target for immunometabolic diseases such as diabetes and atherosclerosis. Herein, we reported the identification of naphthalene-1-sulfonamide derivatives as novel, potent and selective FABP4 inhibitors by applying a structure-based design strategy. The binding affinities of compounds 16dk, 16do and 16du to FABP4, at the molecular level, are equivalent to or even better than that of BMS309403. The X-ray crystallography complemented by the isothermal titration calorimetry studies revealed the binding mode of this series of inhibitors and the pivotal network of ordered water molecules in the binding pocket of FABP4. Moreover, compounds 16dk and 16do showed good metabolic stabilities in liver microsomes. Further extensive in vivo study demonstrated that 16dk and 16do exhibited a dramatic improvement in glucose and lipid metabolism, by decreasing fasting blood glucose and serum lipid levels, enhancing insulin sensitivity, and ameliorating hepatic steatosis in obese diabetic (db/db) mice.

Synthesis, pharmacological activity and comparative QSAR modeling of 1,5-N,N′-substituted-2-(substituted naphthalenesulphonyl) glutamamides as possible anticancer agents

Based on our earlier QSAR study, a series of 1, 5-N,N′-substituted-2-(substituted naphthalenesulphonyl) glutamamides were synthesized as possible anticancer agents. Anticancer activities of these synthesized compounds were evaluated in vivo on Swiss Albino mice against Ehrlich Ascites Carcinoma (EAC) cells where inhibitions of tumor cell and tumor weight were considered as biological activity parameters. A comparative QSAR study was done with a set of descriptors and logarithm of tumor cell inhibition. The result shows the importance of topological parameters like ETSA and RTSA indices as well as electronic parameter like Wang-Ford charges of different atoms. Electrophilic attack at atom number 5 and increased number of chlorine atom may be favorable whereas presence of methoxy group at the atom number 8 in naphthalene ring may be detrimental to the activity.

Substituted Disulfonamide Compounds

Substituted disulfonamide compounds corresponding to formula I: In which R1, R2, R3, R4a, R4b, R5a, R5b, R8, R9a, R9b, R10, R11, a, b, s, t and A have defined meanings, pharmaceutical compositions containing one or more such compounds, processes for preparing such compounds, and a method of using such compounds for the treatment or inhibition of pain and/or other conditions mediated by the bradykinin receptor 1 (BR1).

Bispiperidines as antithrombotic agents

Novel compounds which are inhibitors of the binding of fibrinogen to the Gp IIb/IIIa platelet receptors, and which can be used therepeutically as antithrombotic agents